New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAF<sup>V600E</sup>/VEGFR-2 inhibition, and computational studies
Ahmed Sabt, Mohammed A. Khedr, Wagdy M. Eldehna, Abdelsamed I. Elshamy, Mohamed F. Abdelhameed, Rasha M. Allam, Rasha Z. Batran
Abstract
New pyrazolylindolin-2-one linked coumarin derivatives were designed as dual BRAF V600E /VEGFR-2 inhibitors targeting melanoma cells A375. Docking simulation showed various interactions with the binding residues in BRAF V600E and VEGFR-2 active sites.
Topics & Concepts
MelanomaSorafenibApoptosisCoumarinIC50ChemistryCytotoxicityAngiogenesisDocking (animal)Cancer researchPharmacologyStereochemistryIn vitroMedicineBiochemistryNursingHepatocellular carcinomaOrganic chemistryMelanoma and MAPK PathwaysSynthesis and biological activityComputational Drug Discovery Methods